Why venetoclax is a promising new drug for CLL

Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about venetoclax for chronic lymphocytic leukemia (CLL). Venetoclax has recently been approved by the FDA to treat relapsed CLL patients with the 17p deletion. According to Dr Ghia, the drug showed great efficacy in the Phase I and II trials; it was able to achieve minimal residual (MRD) negativity in a large fraction of patients. He also discusses the risk of tumor lysis syndrome associated with venetoclax and how this has been adressed.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Share this video